FDA Oncology Announcements

Platinum agent × Gynecologic × Clear all

6 Announcements

FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy

Trial: RUBY
Drugs: Jemperli (dostarlimab-gxly) · Anti-PD-1 antibody, carboplatin · Platinum agent, paclitaxel · Taxane
Condition: Gynecologic

FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma

Drugs: Keytruda (pembrolizumab) · Anti-PD-1 antibody, carboplatin · Platinum agent, paclitaxel · Taxane
Condition: Gynecologic

FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer

Drugs: Jemperli (dostarlimab-gxly) · Anti-PD-1 antibody, carboplatin · Platinum agent, paclitaxel · Taxane
Condition: Gynecologic

FDA approves bevacizumab in combination with chemotherapy for ovarian cancer

Drugs: Avastin (bevacizumab) · Anti-VEGFR antibody, carboplatin · Platinum agent, paclitaxel · Taxane
Condition: Gynecologic

FDA approves gemcitabine (Gemzar, Eli Lilly and Company)

Drugs: Gemzar (gemcitabine) · Pyrimidine analog, carboplatin · Platinum agent
Condition: Gynecologic

FDA approves topotecan hydrochloride (hycamtin) in combination with cisplatin for the treatment of Stage IVB recurrent or persistent carcinoma of the cervix

Drugs: Hycamtin (topotecan hydrochloride) · Topoisomerase I inhibitor, cisplatin · Platinum agent
Condition: Gynecologic